FOLFIRI + bevacizumab as second-line therapy for metastatic colorectal cancer pretreated with oxaliplatin: A pooled analysis of published trials

Medical Oncology

Volumn 30, Issue 1, 2013, Pages

  Beretta, Giordano Domenico ^a   Petrelli, Fausto ^b   Stinco, Sergio ^a   Cabiddu, Mary ^b   Ghilardi, Mara ^b   Squadroni, Michela ^a   Borgonovo, Karen ^b   Barni, Sandro ^b  

^a Humanitas Gavazzeni Hospital   (Italy)

^b TREVIGLIO HOSPITAL   (Italy)

Author keywords

Bevacizumab; Colorectal cancer; FOLFIRI; Second line

Indexed keywords

BEVACIZUMAB; CAPECITABINE; FLUOROPYRIMIDINE; FLUOROURACIL; IRINOTECAN; OXALIPLATIN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DRUG DERIVATIVE; FOLINIC ACID; MONOCLONAL ANTIBODY; PLATINUM COMPLEX;

ADVANCED CANCER; ANEMIA; ANOREXIA; BLEEDING; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER SURVIVAL; DIARRHEA; DRUG EFFICACY; EMBASE; FATIGUE; HUMAN; HYPERTENSION; INFARCTION; INFECTION; INTERSTITIAL PNEUMONIA; MEDLINE; METASTATIC COLORECTAL CANCER; MUCOSA INFLAMMATION; NAUSEA AND VOMITING; NEUROPATHY; NEUTROPENIA; OBSERVATIONAL STUDY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PUBLICATION; REVIEW; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; THROMBOEMBOLISM; THROMBOSIS; TREATMENT RESPONSE; VOMITING; WOUND HEALING IMPAIRMENT; COLORECTAL TUMOR; DISEASE FREE SURVIVAL; META ANALYSIS; MORTALITY; PATHOLOGY; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; FLUOROURACIL; HUMANS; LEUCOVORIN; ORGANOPLATINUM COMPOUNDS; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84873459319     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-013-0486-y     Document Type: Review

References (24)

1. Cunningham D, Pyrhönen S, James RD, Punt CJ, Hickish TF, Heikkila R, Johannesen TB, Starkhammar H, Topham CA, Awad L, Jacques C, Herait P. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet. 1998;352(9138):1413-8.
2. Tournigand C, André T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol. 2004;22(2):229-37.
3. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335.
4. Giantonio BJ, Catalano PJ, Meropol NJ, O'Dwyer PJ, Mitchell EP, Alberts SR, Schwartz MA. Benson AB 3rd; Eastern Cooperative Oncology Group Study E3200. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol. 2007;25(12):1539-44.
5. Van Cutsem E, Tabernero J, Lakomy R, et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol. 2012;30:3499.
6. Kato S, Andoh H, Gamoh M, et al. Safety verification trials of mFOLFIRI and sequential IRIS + bevacizumab as first-or second-line therapies for metastatic colorectal cancer in Japanese patients. Oncology. 2012;83(2):101-7.
7. Yildiz R, Benekli M, Ozkan M, et al. Bevacizumab every 4 weeks is as effective as every 2 weeks in combination with biweekly FOLFIRI in metastatic colorectal cancer. J Cancer Res Clin Oncol. 2012;138(11):1845-52.
8. Moriwaki T, Bando H, Takashima A, et al. Bevacizumab in combination with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) in patients with metastatic colorectal cancer who were previously treated with oxaliplatin-containing regimens: a multicenter observational cohort study (TCTG 2nd-BV study). Med Oncol. 2012;29(4):2842-8.
9. Horita Y, Yamada Y, Kato K et al. Phase II clinical trial of second-line FOLFIRI plus bevacizumab for patients with metastatic colorectal cancer: AVASIRI trial. Int J Clin Oncol. 2011.
10. Bennouna J, Borg C, Delord JP, et al. Bevacizumab combined with chemotherapy in the second-line treatment of metastatic colorectal cancer: results from the phase II BEVACOLOR study. Clin Colorectal Cancer. 2012;11(1):38-44.
11. Suenaga M, Matsusaka S, Ueno M, et al. Predictors of the efficacy of FOLFIRI plus bevacizumab as second-line treatment in metastatic colorectal cancer patients. Surg Today. 2011;41(8):1067-74.
12. Sogabe S, Komatsu Y, Yuki S, et al. Retrospective cohort study on the safety and efficacy of bevacizumab with chemotherapy for metastatic colorectal cancer patients: the HGCSG0801 study. Jpn J Clin Oncol. 2011;41(4):490-7.
13. Bendell JC, Tournigand C, Bednarczyk M et al. Axitinib or bevacizumab (bev) plus FOLFOX or FOLFIRI as second-line therapy in patients (pts) with metastatic colorectal cancer (mCRC). J Clin Oncol. 2011;29(suppl. 1):4.
14. Odabas H, Abali H, Kos FT et al. Eficacy and safety of FOLFIRI-bevacizumab for the second-line treatment of metastatic colorectal carcinoma. Ann Oncol. 2010;8 (viii218, 21 suppl).
15. Kwon HC, Oh SY, Lee S, Kim SH, Kim HJ. Bevacizumab plus infusional 5-fluorouracil, leucovorin and irinotecan for advanced colorectal cancer that progressed after oxaliplatin and irinotecan chemotherapy: a pilot study. World J Gastroenterol. 2007;13(46):6231-5.
16. Stinco S, Squadroni M, Ripa C et al. FOLFIRI plus bevacizumab as second-line therapy in metastatic colorectal cancer (MCRC). Tumori 2012; 13 (3), S48 (abstr B58).
17. Petrelli F, Borgonovo K, Cabiddu M, Ghilardi M, Barni S. Cetuximab and panitumumab in KRAS wild-type colorectal cancer: a meta-analysis. Int J Colorectal Dis. 2011;26(7):823-33.
18. Petrelli F, Barni S. Correlation of progression-free and post-progression survival with overall survival in advanced colorectal cancer. Ann Oncol. 2012.
19. Bidard FC, Tournigand C, André T, et al. Efficacy of FOLFIRI-3 (irinotecan D1, D3 combined with LV5-FU) or other irinotecan-based regimens in oxaliplatin-pretreated metastatic colorectal cancer in the GERCOR OPTIMOX1 study. Ann Oncol. 2009;20(6):1042-7.
20. Ducreux M, Malka D, Mendiboure J, et al. Sequential versus combination chemotherapy for the treatment of advanced colorectal cancer (FFCD 2000-05): an open-label, randomised, phase 3 trial. Lancet Oncol. 2011;12(11):1032-44.
21. Arnold D, Andre T, Bennouna J et al. Bevacizumab (BEV) plus chemotherapy (CT) continued beyond first progression in patients with metastatic colorectal cancer (mCRC) previously treated with BEV plus CT: results of a randomized phase III intergroup study (TML study). J Clin Oncol. 2012;30(suppl)(abstr CRA3503).
22. Lièvre A, Samalin E, Mitry E, et al. Bevacizumab plus FOLFIRI or FOLFOX in chemotherapy-refractory patients with metastatic colorectal cancer: a retrospective study. BMC Cancer. 2009;28(9):347.
23. Vale CL, Tierney JF, Fisher D, et al. Does anti-EGFR therapy improve outcome in advanced colorectal cancer? A systematic review and meta-analysis. Cancer Treat Rev. 2012;38(6):618-25.
24. Brouquet A, Overman MJ, Kopetz S, et al. Is resection of colorectal liver metastases after a second-line chemotherapy regimen justified? Cancer. 2011;117(19):4484-92.